Press releases
Atalanta Therapeutics Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer
May 22, 2024
– Serena Hung, M.D., and Jeffrey Young will support company’s continued progress, including two planned IND submissions in 2025 – BOSTON, May 22, 2024 – Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the expansion of its executive team with the appointments of Serena Hung, M.D., as […]
Atalanta Therapeutics Appoints Alfred Sandrock to Board of Directors
March 10, 2022
BOSTON, March 10, 2022 — Atalanta Therapeutics, a biotechnology company pioneering new treatment options for CNS diseases utilizing its proprietary branched siRNA platform, today announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D. to the company’s Board of Directors. In this capacity, Dr. Sandrock will work closely with Atalanta’s leadership team to inform the […]
Atalanta Therapeutics Strengthens Leadership Team with Key Appointments in R&D and Corporate Development
October 7, 2021
BOSTON, October 7, 2021 – Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, today announced the expansion of its leadership team with three new appointments: Morgan Molloy as chief corporate development officer; Stefan McDonough as vice president, head of neuroscience; and Garth Kinberger as vice president of chemistry. “We are thrilled […]
Atalanta Therapeutics to Present at Stifel 3rd Annual CNS Day
March 31, 2021
BOSTON–(BUSINESS WIRE)–Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, announced today that Alicia Secor, president and chief executive officer, and Aimee L. Jackson, Ph.D., chief scientific officer, are scheduled to participate virtually in an analyst-led fireside chat at the Stifel 3rd Annual CNS Day on Thursday, April 1, 2021 at 1:30 pm […]
Atalanta Therapeutics Launches With $110 Million to Pioneer RNAi Therapeutics for Neurodegenerative Diseases
January 11, 2021
Announces strategic collaborations with Biogen, Genentech to develop RNAi therapeutics for neurodegenerative diseases Founders are world-leading experts in RNA interference, including Nobel laureate Craig Mello Company has assembled a first-class management team of industry veterans helmed by CEO Alicia Secor BOSTON, Mass. – Jan. 11, 2021 – Atalanta Therapeutics, a biotechnology company pioneering new treatment […]